Target market Medical device company focused on hemorrhage control with FDA cleared partial REBOA catheter, presenting a clear procurement opportunity for trauma centers, emergency departments, and surgical suites seeking advanced hemostasis and improved patient outcomes.

Clinical leadership Recent hires and advisory appointments (CEO Spalding, Clinical Advisory Board member Robert A. Cohen, Chief Commercialization Officer Donna Syracuse) indicate a strategic push toward clinical validation, education, and market adoption, signaling readiness for partnerships, training programs, and key account initiatives.

Product advantage Flagship pREBOA-PRO catheter offers True Partial REBOA with continuous distal blood flow, differentiating from full occlusion devices and aligning with surgeons’ need for proximal control and tissue perfusion, a compelling value proposition for trauma and critical care buyers.

Expansion opportunities Track record of product launches since 2020 and ongoing commercialization leadership suggest potential for expansion into additional US hospitals, regional trauma networks, and ER-driven accounts, as well as opportunities for bundled training and service contracts.

Strategic partnerships Strong leadership, board-level and advisory involvement, and a focused tech stack position Prytime for collaborations with hospital systems, distributors, and research institutions to accelerate adoption, clinical studies, and reimbursement support.